Major Depression
Conditions
Keywords
Major Depression, Pindolol, Venlafaxine, Augmentation, Major depression (DSM-IVR)
Brief summary
This study investigates the hypothesis that pindolol can accelerate the response to antidepressants in patients with major depression treated with venlafaxine.
Detailed description
Antidepressant therapy has a delayed onset of action of 4-6 weeks. Pindolol has in some studies shown an accelerating effect. In this study we investigate the effect of 20 mg of pindolol retarded formulation in combination with Venlafaxine compared to placebo Pindolol and Venlafaxine for a duration of 19 days. Effect is measured by the Hamilton Depression rating Scale and the Preskorn Scale (self-rating).
Interventions
DRUGPindolol and venlafaxin
pindolol 20 mg and venlafaxin 150 mg
Sponsors
Wyeth is now a wholly owned subsidiary of Pfizer
Tvergaards Foundation
Hillerod Hospital, Denmark
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Major depression
Exclusion criteria
* Allergy towards pindolol, venlafaxine or other tablet constituents * Liver or kidney impairment * Diabetics * Age below 18 years * Severe cardiac disease * Asthma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Depression Rating Scale scores | 1 week |
Secondary
| Measure | Time frame |
|---|---|
| Preskorn scores | one day |
Countries
Denmark
Outcome results
None listed